



Research Article

A Randomized Controlled Clinical Study to Evaluate Add-on Effect of *Baladi* Granules in the Management of *Karshya Vyadhi* (Mild to Moderate Undernutrition) in Children

Mosim Momin^{1*}, Deepak Khawale², Abhijeet Shirkande³, Farheen Shaikh⁴

1. PhD Scholar, Kaumarbhritya Department, Dr. D. Y. Patil College of Ayurved and Research Centre Pimpri, Pune; Dr. D. Y. Patil Vidyapeeth Pune (Deemed to be University), Pimpri, Pune 18. India.
2. Professor & HOD, Kaumarbhritya Department, Dr. D. Y. Patil College of Ayurved and Research Centre Pimpri, Pune; Dr. D. Y. Patil Vidyapeeth Pune (Deemed to be University), Pimpri, Pune 18. India.
3. Associate Professor, Department of Dravyaguna (Ayurvedic Materia Medica & Pharmacology), Dr. D. Y. Patil College of Ayurved & Research Center, Pimpri, Pune of Dr. D. Y. Patil Vidyapeeth (Deemed to be University), Pimpri, Pune, India.
4. PG Scholar Prasuti tantra evam Stri Roga Department, Shri Dhanwantri Ayurvedic Medical College and Research centre, 27 km. milestone, Mathura- Delhi Highway, Chhata, Mathura (U.P). India.

Received: 24-11-2025

Accepted: 19-06-2026

Published: 30-06-2026

Abstract

Background: Protein-energy malnutrition is a major contributor to childhood morbidity and mortality in India, with one-third of children under five undernourished. Ayurveda describes *Karshya Vyadhi* as undernutrition, managed with *Brimhana* and *Balya* therapies. *Baladi* Granules, a polyherbal, child-friendly formulation (*Sida cordifolia*, *Withania somnifera*, *Asparagus racemosus*, *Glycyrrhiza glabra*, *Saccharum officinarum*, with *Zingiber officinale* and *Elettaria cardamomum*), were developed to improve appetite, digestion, and growth. **Materials and Methods:** A randomized, controlled, open-label clinical trial was conducted on 122 children (1–12 years) with mild-to-moderate undernutrition (weight-for-age 60–80%, IAP classification) at Dr. D. Y. Patil Ayurved Hospital, Pimpri, Pune. Participants were randomized into Group A (*Baladi* Granules + standard undernutrition diet) and Group B (diet alone). Intervention lasted 30 days. Primary outcome was change in weight-for-age and body weight; secondary outcomes included MUAC, height-for-age, muscle wasting, hunger, general appearance, weakness, adherence, and safety. **Results:** Out of 122 enrolled, 116 completed the trial. Group A demonstrated significantly greater mean weight gain (0.48 kg vs. 0.26 kg), MUAC improvement (0.43 cm vs. 0.30 cm), and more linear growth (0.64 cm vs. 0.41 cm) compared to controls. Subjective parameters (hunger, general appearance, weakness, muscle wasting) also improved more in Group A, with 53.45% showing marked improvement versus 20.69% in controls. No adverse events were reported. **Conclusions:** *Baladi* Granules, as an adjunct to diet, are safe, palatable, and effective in improving anthropometric and clinical outcomes in children with undernutrition. Further large-scale studies are warranted.

Keywords: *Karshya Vyadhi*, *Baladi* Granules, Undernutrition, *Ayurveda*, Children, Randomized controlled trial

Access this article
online

Website:
<https://ijam.co.in>



DOI: <https://doi.org/10.47552/ijam.v17i2.6750>

Introduction

Protein energy malnutrition remains one of the leading contributors to morbidity and mortality among children in India. Undernutrition accounts for nearly 45% of global mortality among children below five years of age(1). The National Family Health

Survey (NFHS-4) reports that 36% of children under five in India are underweight, with the burden being greater in rural than in urban areas. In Pune, undernutrition affects 27.9% of the rural pediatric population compared to 23.6% in urban areas(2). The prevalence is similar in boys and girls. Undernutrition during early childhood can result in irreversible physical, cognitive, and developmental impairments.

Ayurveda describes *Karshya Vyadhi* as a state of undernutrition, and several classical formulations including *Preenan Modak*(3), *Balpanchamruta Churna*(4), *Pathadi Churna*(5), and *Vachadi Ghrita*(6) have demonstrated benefits in improving body weight and nutritional status in children. Many existing studies are constrained by factors such as limited sample sizes, brief

* Corresponding Author:

Mosim Momin

PhD Scholar, Kaumarbhritya Department, Dr. D. Y. Patil College of Ayurved and Research Centre Pimpri, Pune; Dr. D. Y. Patil Vidyapeeth Pune (Deemed to be University), Pimpri, Pune 18 India.

Email Id: dr.mosim2010@gmail.com

treatment durations, and reliance on single-arm methodologies. Additionally, traditional Ayurvedic dosage forms like *Churna* and *Ghrita*, though efficacious, are often unpalatable and inconvenient for pediatric administration.

There remains a lack of large-scale randomized controlled trials evaluating child-friendly, palatable Ayurvedic dosage forms. *Baladi* Granules have been formulated to address this gap, containing *Bala* (*Sida cordifolia*), *Shatavari* (*Asparagus racemosus*), *Ashwagandha* (*Withania somnifera*), *Yashtimadhu* (*Glycyrrhiza glabra*), *Khand* (*Saccharum officinarum*), *Shunthi* (*Zingiber officinale*), and *Ela* (*Elettaria cardamomum*). These ingredients are cost-effective, widely available, and safe for pediatric use.

Since children with undernutrition require dietary support beyond a normal diet and protein supplements may be unsuitable for children under three years due to renal immaturity(7). For children aged 1–12 years with mild to moderate undernutrition (*Karshya Vyadhi*), *Baladi* Granules serve as a holistic, safe, and child-friendly therapeutic alternative.

Materials and methods


Research design

The Kaumarbhritya Department of the Dr. D. Y. Patil Ayurved Hospital and Research Centre Pimpri, Pune, was the site of this prospective, open-label, randomized, controlled clinical study. The trial lasted 36 months in total.

Participants

A total of 122 children (aged 1–12 years) with mild-to-moderate undernutrition (weight-for-age 60–80%, IAP classification) were enrolled after obtaining parental informed consent(8). Children with severe undernutrition, chronic or infective diseases, immunodeficiency, inborn errors of metabolism, malignancies, or genetic disorders were excluded.

Participants were randomized (block randomization; chit-in-envelope) into two equal groups: Group A (Trial, n = 61): *Baladi* Granules (1 g/year of age, twice daily with 100 mL milk before meals at 08:00 and 18:00) plus standard undernutrition diet (IAP guidelines) (9). Group B (Control, n = 61): Standard undernutrition diet alone(10). Intervention lasted 30 days with follow-ups on Days 15 and 30. Adherence was assessed via caregiver charts and unused drug counts. Withdrawal criteria were refusal, migration, or adverse effects.



Drug Preparation Method

Baladi Granules were prepared following standard Ayurvedic procedures. Cleaned crude drugs were processed into decoction, filtered, and mixed with sugar. The mixture was stirred to semi-solid consistency, converted into granules, sieved, dried, and stored in airtight containers. (see supplementary files for more details)

Institutional Ethics Committee Ref. No: DYPCARC/IEC/99/2023

CTR Registration Number: CTRI/2024/03/063618

Primary Outcome

Criteria for Assessment

Primary Outcome:

- **Weight-for-Age (IAP Classification):** Improvement in nutritional status based on weight-for-age percentage.
- **Primary endpoint:** Mean change in body weight (kg) from baseline to Day 30.

Secondary Outcomes:

- **Anthropometric:** MUAC (Arnold's classification) (11), Height-for-Age(12).
- **Subjective:** State of Hunger (*Kshudha*) (13), General Appearance (*Darshana*) (13), and General Weakness (*Daurbalya*) (14), clinical assessment of muscle wasting (*Shushkaspahik-Udar-Griva*) (15).
- **Other:** Treatment adherence (drug accountability/caregiver charts) and safety outcomes (adverse drug reactions).

Assessment Schedule

All parameters were assessed at baseline, Day 15, and Day 30 using predefined grading scales. Cumulative scores were compared to evaluate clinical improvement.

Statistical Analysis

A total of 122 children were recruited, with 61 allocated to each group. Three participants from both the trial and control groups discontinued, resulting in 58 subjects per group included in the final evaluation. Demographic data were expressed as frequencies and percentages and represented graphically. Ordinal variables were examined using the Wilcoxon signed-rank test for intra-group comparisons and the Mann–Whitney U test for inter-group analyses. Continuous data were evaluated using paired and unpaired t-tests, as the population standard deviation was not known. A p-value < 0.05 was deemed statistically significant, and all analyses were performed using SPSS software version 20.0 (IBM Corp., Armonk, NY, USA).

Observations and Results

A total of 122 children were enrolled, with 61 in each group. The average age of participants was 4.35 ± 2.56 years in Group A and 5.20 ± 3.08 years in Group B. Gender distribution was nearly equal, with 31 males and 30 females in each group. The majority of participants were Hindu, accounting for 88.5% in Group A and 96.7% in Group B, from middle socioeconomic class (70.5% and 67.2% respectively), and followed a mixed diet (63.9% and 80.3%). *Prakruti* analysis showed VP type as predominant in both groups. Baseline characteristics including age, sex, religion, socioeconomic status, diet, and *prakruti* were comparable between groups, confirming successful randomization.

Table 1: Patient Profile

| Sr. No. | Clinical Profile | | Group A (Trial) | Group B (Control) |
|---------|-----------------------|----------|-----------------|-------------------|
| 1 | Age (Years) | | 4.35 ± 2.56 | 5.20 ± 3.08 |
| 2 | Sex | Male | 31 (50.82%) | 31 (50.82%) |
| | | Female | 30 (49.18%) | 30 (49.18%) |
| 3 | Religion | Buddhist | 1 (1.64%) | 0 (0.00%) |
| | | Hindu | 54 (88.52%) | 59 (96.72%) |
| | | Jain | 1 (1.64) | 0 (0.00%) |
| | | Muslim | 5 (8.20) | 2 (3.28%) |
| 4 | Socio Economic Status | Lower | 7 (11.48%) | 13 (21.13%) |
| | | Middle | 43 (70.49%) | 41 (67.21%) |
| | | Higher | 11 (18.03%) | 7 (11.48%) |
| 5 | Diet | Mixed | 39 (63.93%) | 49 (80.33%) |
| | | Veg | 22 (36.07%) | 12 (19.67%) |
| 6 | Prakruti | KP | 15 (24.59%) | 18 (29.51%) |
| | | KV | 4 (6.56%) | 1 (1.64%) |
| | | PK | 4 (6.56%) | 2 (3.28%) |
| | | PV | 3 (4.92%) | 4 (6.56%) |
| | | VK | 1 (1.64%) | 4 (6.56%) |
| | | VP | 34 (55.74%) | 32 (52.46%) |

Objective Parameters**Table 2: Objective parameters**

| Sr. No | Clinical Variables | Groups | 1st Day | 15th Day | 30th Day | P-Value |
|--------|--------------------|-------------|----------------|----------------|----------------|---------|
| 1 | Weight for Age | A (Trial) | 13.74 ± 4.58 | 14.00 ± 4.60 | 14.22 ± 4.59 | <0.001 |
| | | B (Control) | 15.56 ± 5.67 | 15.68 ± 5.68 | 15.82 ± 5.67 | <0.001 |
| 2 | MUAC | A (Trial) | 15.38 ± 1.43 | 15.44 ± 1.44 | 15.80 ± 1.43 | <0.001 |
| | | B (Control) | 15.86 ± 1.62 | 15.89 ± 1.65 | 16.16 ± 1.72 | <0.001 |
| 3 | Height for Age | A (Trial) | 98.17 ± 17.52 | 98.49 ± 17.48 | 98.81 ± 17.43 | <0.001 |
| | | B (Control) | 104.84 ± 21.10 | 104.97 ± 21.10 | 105.25 ± 21.10 | <0.001 |

Clinical Assessment Outcomes (Objective parameters)

Both groups showed significant improvements in anthropometric indicators ($p < 0.001$). In the Trial group, Weight for Age increased by 3.48% compared to 1.64% in the Control group, while MUAC improved by 2.77% versus 1.90% in controls. Height for Age showed minimal change in both groups (<1%). Overall, the Trial group demonstrated earlier and greater gains, particularly in Weight for Age and MUAC, indicating a more pronounced effect of *Baladi* Granules on nutritional status.

Subjective Parameters**Table 3: Subjective parameters**

| Sr. No | Clinical Variables | Groups | 1st Day | 15th Day | 30th Day | P-Value |
|--------|--------------------|-------------|-------------|-------------|-------------|---------|
| 1 | State of Hunger | A (Trial) | 1.60 ± 0.59 | 0.67 ± 1.55 | 0.00 ± 0.00 | <0.001 |
| | | B (Control) | 1.67 ± 0.47 | 1.55 ± 0.50 | 0.71 ± 0.59 | <0.001 |
| 2 | General appearance | A (Trial) | 1.33 ± 0.54 | 1.29 ± 0.53 | 0.71 ± 0.59 | <0.001 |
| | | B (Control) | 1.19 ± 0.40 | 1.17 ± 0.42 | 0.88 ± 0.50 | <0.001 |
| 3 | General Weakness | A (Trial) | 1.16 ± 0.37 | 0.34 ± 0.55 | 0.05 ± 0.22 | <0.001 |
| | | B (Control) | 1.19 ± 0.40 | 1.10 ± 0.36 | 0.26 ± 0.55 | <0.001 |
| 4 | Wasting of muscles | A (Trial) | 1.31 ± 0.47 | 1.26 ± 0.44 | 0.45 ± 0.54 | <0.001 |
| | | B (Control) | 1.19 ± 0.40 | 1.19 ± 0.40 | 0.59 ± 0.62 | <0.001 |

Clinical Assessment Outcomes (Subjective Parameters)

Both groups showed significant improvements ($p < 0.001$) in hunger, general appearance, weakness, and muscle wasting. In the Trial group, State of Hunger improved completely by day 30 (100% vs. 57.7% in controls). General Appearance improved by

46.8% compared to 26.1% in the Control group. General Weakness showed 95.5% improvement versus 78.3% in controls. Muscle Wasting reduced by 65.8% compared to 50.7% in controls. Overall, the Trial group demonstrated earlier, faster, and greater improvements across all subjective parameters, confirming the superior efficacy of *Baladi* Granules as an add-on therapy.

Table 4: Overall improvement in Group A (Trial) and Group B (Control) according to number of patients.

| Overall Effect | Group A (Trial) | | Group B (Control) | |
|----------------------|-----------------|---------|-------------------|---------|
| | N | % | N | % |
| Marked Improvement | 31 | 53.45% | 12 | 20.69% |
| Moderate Improvement | 24 | 41.38% | 22 | 37.93% |
| Mild Improvement | 3 | 5.17% | 15 | 25.86% |
| No Improvement | 0 | 0.00% | 9 | 15.52% |
| TOTAL | 58 | 100.00% | 58 | 100.00% |

In Group A, 53.45% of patients showed marked improvement (>75%), 41.38% demonstrated moderate improvement (51–75%), and 5.17% exhibited mild improvement (26–50%). In contrast, Group B showed marked improvement in 20.69%, moderate improvement in 37.93%, mild improvement in 25.86%, and no improvement in 15.52% of patients.

Discussion

According to Ayurveda Karshya is defined as a lean and thin body constitution (*Krishna Sharira*), primarily resulting from *Dhatukshaya*, with a special emphasis on *Mamsakshaya*(16). Charaka Samhita describes symptoms like poor tolerance to exertion, hunger, thirst, and climate extremes. Clinically, it presents with emaciation, sunken buttocks, abdomen, and neck, and visible veins (*Shushka sphik-udara-greeva*) (15). These findings resemble biomedical undernutrition, marked by low weight-for-age and muscle wasting. Thus, Karshya correlates closely with undernutrition, bridging Ayurvedic and modern perspectives.

This randomized controlled trial was conducted to assess the adjunctive efficacy of Baladi Granules in managing mild-to-moderate undernutrition (Karshya Vyadhi) among children. Demographic analysis revealed that most participants were aged 1–5 years, highlighting the higher vulnerability of early childhood to undernutrition. Gender distribution was balanced, indicating no sex-related bias. The majority belonged to the middle socio-economic class and followed a mixed diet, consistent with local population characteristics. Predominant *Vata–Pitta Prakriti* was observed, which aligns with Ayurvedic concepts, as *Vata* dominance predisposes to lean body habitus, variable appetite, and *dhātu kṣaya*.

Objective anthropometric outcomes demonstrated significant improvements in both groups, with superior results in the trial group receiving *Baladi Granules*. Children in Group A showed greater mean weight gain (0.48 kg vs. 0.26 kg), higher MUAC improvement (0.43 cm vs. 0.30 cm), and more linear growth (0.64 cm vs. 0.41 cm) compared to controls. These results suggest that *Baladi Granules* contributed to better weight restoration, muscle development, and growth.

Subjective parameters further supported these findings. Group A demonstrated marked improvements in appetite, general appearance, and vitality compared to controls. Clinical assessments revealed faster recovery in hunger perception (*Kshudha*), better physical outlook (*Darshana*), and reduced weakness (*Daurbalya*). Reduction in muscle wasting was also more pronounced in Group A, reflecting enhanced tissue nourishment. Overall response rates indicated that 53.45% of children in Group A achieved marked improvement, compared to only 20.69% in Group B, while none in the trial group remained unimproved. This highlights the efficacy of the formulation in improving both physical and functional health outcomes.

The therapeutic effects of *Baladi Granules* can be explained through Ayurvedic principles and modern pharmacology. The dose of *Baladi Granules* was based on the age-wise pediatric dosing principles described in Sharangadhara Samhita (Prathama Khanda 6/14–16). Since the formulation was administered in a coarse granule form, it was considered analogous to Churna Kalpana, and the dose was fixed as 1 g per year of age, twice daily. The formulation possesses *Brimhana* (bulk-promoting), *Balya* (strength-promoting), *Rasayana* (rejuvenative), and *Vata-pacifying* properties, which enhance *Agni*, assimilation, and *dhātu poṣhana*(17)(18)(19). The key ingredients *Sida cordifolia*, *Withania somnifera*, *Asparagus racemosus*, *Glycyrrhiza glabra*, and *Saccharum officinarum* support muscle mass, immunity, digestion, and energy(20)(21)(22). The adjuvants *Zingiber officinale* and *Elettaria cardamomum* act as *Deepana* and *Pachana*, improving appetite and reducing gastrointestinal discomfort(18)(23). Collectively, these actions facilitated faster weight gain, improved MUAC, and better overall growth in undernourished children.

In addition, the standard undernutrition diet, designed according to IAP guidelines and enriched with calorie-dense and protein-rich foods, played a crucial role in recovery across both groups. High-calorie items (ghee, cashews, jaggery), protein sources (soybeans, eggs, chicken), and micronutrient-rich foods (pulses, fish, almonds) promoted weight gain, tissue repair, and immune function(24). Fermented foods and buttermilk improved gut health, while culturally acceptable items ensured dietary adherence. While both groups benefited from diet, the trial group exhibited accelerated and greater improvements due to the synergistic effect of *Baladi Granules*. Both groups maintained a steady post-intervention weight gain of 300–400 g per month, indicating sustained nutritional recovery. Thus, the study concludes that *Baladi Granules* are a safe and effective adjunct to standard dietary therapy in pediatric undernutrition, warranting further large-scale and long-term studies for confirmation.

Conclusion

Baladi Granules, as an adjunct to standard undernutrition diet, significantly improved weight, MUAC, and height in children with mild to moderate undernutrition. The formulation is safe, cost-effective, and showed no adverse effects, highlighting its potential as a supportive therapy in pediatric nutrition.

Source of funding: It is entirely self-funded.

Acknowledgement: The author thanks the postgraduate students, participants, and their parents for their support, and expresses gratitude to family and friends for their encouragement.

Conflicts of Interest: None declared.

References

1. Paul VK, Bagga A. *Ghai Essential Pediatrics*. 9th ed. Reprint 2021. New Delhi: CBS Publishers & Distributors; 2019. p.94.
2. International Institute for Population Sciences (IIPS) and ICF. *National Family Health Survey (NFHS-4), 2015–16: District Fact Sheet, Pune, Maharashtra*. Mumbai: Ministry of Health and Family Welfare, Government of India; 2017.
3. Saroj AKR, Khawale DS. To study the efficacy of Preenan Modak described in Ashtang Hriday for the management of Karshya with special reference to undernutrition in the age group of 1 to 6 years: A randomized controlled study [MD thesis]. Pune: DPU; 2020.

4. Doshi AM, Khawale DS. A single-arm clinical study to evaluate the effect of Balpanchamruta Churna in the management of Karshya Vyadhi (underweight) in children [MD thesis]. Pune: DPU; 2022.
5. Rathi RB, Kurhadkar M, Rathi BJ, Khobragade S, Khedekar S. A comparative study on the effectiveness of *Pathadi Churna* and protein powder in *Karshya* (undernutrition) among preschool children. *Int J Ayurvedic Med*. 2023;14(3):696–702. Available from: <http://ijam.co.in/DMIHER>.
6. Mhaske V, Rajpal R. A single-arm clinical study to evaluate the efficacy of Vachadi Ghrith in the management of Karshya Vyadhi (undernutrition) [MD thesis]. Pune: DPU; 2025.
7. Garcia-Iborra M, Castanys-Munoz E, Oliveros E, Ramirez M. Optimal Protein Intake in Healthy Children and Adolescents: Evaluating Current Evidence. *Nutrients*. 2023;15(7):1683. doi:10.3390/nu15071683.
8. Paul VK, Bagga A. Ghai essential pediatrics. 8th ed. Reprint 2017. New Delhi: CBS Publishers & Distributors; 2013. p.97.
9. Murthy KRS. Sharangadhara Samhita. Reprint ed. Varanasi: Chaukhamba Orientalia; 2012. Pratham Khanda 6/14–16. p.29.
10. Parthasarathy A, Menon PSN, Nair MKC. *IAP Textbook of Pediatrics*. Reprint ed. New Delhi: Jaypee Brothers Medical Publishers; 2019. p.197.
11. Parthasarathy A, Menon PSN, Nair MKC. *IAP Textbook of Pediatrics*. Reprint ed. New Delhi: Jaypee Brothers Medical Publishers; 2019. p.186.
12. Singh M. *Pediatric Clinical Methods*. 3rd ed. Reprint 2006. New Delhi: Sagar Publications; p.55.
13. Mitra J. *Ashtanga Samgraha: Sasilekha Sanskrit Commentary*. Reprint ed. Varanasi: Chaukhamba Prakashan; 2008. Uttar Tantra 2/34. p.643.
14. Shastri L. *Yogratnakar: Vidyotini Hindi Commentary*. Reprint ed. Varanasi: Chaukhamba Prakashan; 2017. Balrogadhikar. p.444.
15. Sastri K, Chaturvedi G. *Charaka Samhita: Vidyotini Hindi Commentary*. Reprint ed. Varanasi: Chaukhamba Prakashan; 2009. Sutrasthana 21/13,15. p.412.
16. Sushruta. *Sushruta Samhita*, Sutrasthana 15/13, with Dalhana commentary. Varanasi: Chaukhamba Surbharati Prakashan; Reprint 2020.
17. Pandey GS, Chuneekar KC. *Bhavaprakasha Nighantu: Commentary*. Reprint ed. Varanasi: Chaukhamba Bharati Academy; 2015. Guduchyadi Varga 144,190,187. p.351,379,378.
18. Pandey GS, Chuneekar KC. *Bhavaprakasha Nighantu: Commentary*. Reprint ed. Varanasi: Chaukhamba Bharati Academy; 2015. Haritakyadi Varga 146,45. p.62,12.
19. Pandey GS, Chuneekar KC. *Bhavaprakasha Nighantu: Commentary*. Reprint ed. Varanasi: Chaukhamba Bharati Academy; 2015. Ekshu Varga 29. p.780.
20. Choudhary D, Bhattacharyya S, Bose S. Efficacy and safety of Ashwagandha (*Withania somnifera*) root extract in improving cardiorespiratory endurance in healthy athletic adults: A double-blind, placebo-controlled randomized clinical trial. *Journal of Dietary Supplements*. 2022;19(4): 464-82. doi:10.1080/19390211.2022.2059967.
21. Asparagus racemosus Willd. aqueous root extract enhances immune response in animals immunized with DPT vaccine, significantly increasing antibody titres and reducing mortality upon challenge. *International Journal of Immunopharmacology*.
22. Patil RA, Jagdale SC, Kasture SB. Antistress, adaptogenic activity of *Sida cordifolia* roots in mice: increased swim endurance, reduced corticosterone, and enhanced antioxidant status. *Indian Journal of Experimental Biology*. 2006;44(12):987-92
23. Sharma P. *Dhanvantari Nighantu: Jaikrishnadas Ayurved Series 40*. Reprint ed. Varanasi: Chaukhamba Orientalia; 2016. Shatpushpadi Dvitiyovarga 45. p.78.
24. Paul VK, Bagga A. *Ghai Essential Pediatrics*. 8th ed. Reprint 2017. New Delhi: CBS Publishers & Distributors; 2013. p.92.
